Northwest Biotherapeutics (NWBO) Net Cash Flow Growth (3y) (2013 - 2026)
Northwest Biotherapeutics (NWBO) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 32.17% |
| 10 | Northwest Biotherapeutics | 277.35 Mn | 275.56 Mn | - | -601.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -601.29% |
| Dec 31, 2025 | -100.70% |
| Sep 30, 2025 | -197.65% |
| Jun 30, 2025 | 46.24% |
| Mar 31, 2025 | 30.92% |
| Dec 31, 2024 | -33.83% |
| Sep 30, 2024 | 82.67% |
| Jun 30, 2024 | 28.45% |
| Mar 31, 2024 | 41.17% |
| Dec 31, 2023 | -46.53% |
| Sep 30, 2023 | -17.08% |
| Jun 30, 2023 | -39.90% |
| Mar 31, 2023 | 26.36% |
| Dec 31, 2022 | 33.08% |
| Sep 30, 2022 | 73.22% |
| Jun 30, 2022 | 20.72% |
| Mar 31, 2022 | -15.07% |
| Dec 31, 2021 | -18.93% |
| Sep 30, 2021 | 26.67% |
| Jun 30, 2021 | -27.36% |